why choose us

Course: Acute Allergic Reactions to mRNA COVID-19 Vaccines

CME Credits: 1.00

Released: 2021-03-08

Anaphylaxis to the mRNA COVID-19 vaccines is currently estimated to occur in 2.5 to 11.1 cases per 1 million doses, largely in individuals with a history of allergy. Allergic concerns contribute to vaccine hesitancy; we investigated acute allergic reaction incidence after more than 60,000 mRNA COVID-19 vaccine administrations.
We prospectively studied Mass General Brigham (MGB) employees who received their first dose of an mRNA COVID-19 vaccine (12/16/2020-2/12/2021, with follow-up through 2/18/2021) (eMethods in the ). For 3 days after vaccination, employees completed symptom surveys through a multipronged approach including email, text message, phone, and smartphone application links. Acute allergic reaction symptoms solicited included itching, rash, hives, swelling, and/or respiratory symptoms (eAppendix in the ).


Educational Objective
To identify the key insights or developments described in this article


View Full Course